|
⚲
|
| Keyboard |
| Medicxi Ventures Management Jersey Limited
✚
|
|
|---|---|
| CRD # | 283504 |
| SEC # | 802-108259 |
| CIK # | 0001715579 |
| AUM | |
| Employees | |
| Phone | 441534713740 |
| Address | 44 Esplanade St Helier, Jersey |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Newamsterdam Pharma Co NV | 85.6 | ||
| Phathom Pharmaceuticals Inc | 82.9 | ||
| AURA Biosciences Inc | 20.3 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Medicxi V LP | [2026-02-26] | 290.2 M | 585.0 M |
| Filed 2025-09-26 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Medicxi IV LP | [2023-03-31] | 195.4 M | 328.9 M |
| Filed 2022-05-24 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Medicxi Secondary I LP | [2021-03-16] | 95.1 M | 554.6 M |
| Offered $95,062,180 · Filed 2020-09-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Medicxi III LP | [2020-03-30] | 260.3 M | 510.9 M |
| Filed 2019-07-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Medicxi Growth I LP | [2016-08-08] | 22.1 M | 223.8 M |
| Filed 2016-11-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Medicxi Ventures I LP | [2016-08-08] | 116.9 M | 239.8 M |
| Offered $116,898,500 · Filed 2015-10-21 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Charles Le Cornu | Director | 7 | 7 | |
| Francois Chesnay | Director | 10 | 4 | |
| Kevin Johnson | Executive Officer | 68 | 3 | |
| Francesco de Rubertis | Executive Officer | 17 | 2 | |
| Michele Ollier | Executive Officer | 14 | 2 | |
| David Grainger | Executive Officer | 4 | 2 | |
| Giuseppe Zocco | Executive Officer | 2 | 1 | |
| Giovanni Pericolini | Director | 2 | 1 | |
| Louisa Blanchet | Director | 1 | 1 | |
| Christopher Patton | Director | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001715579] | |
| 3 | [0001715579] | |
| 4 | [0001715579] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2022-03-21 | Other | 45,054 | $0.00 | |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2022-03-21 | Other | 1,794,211 | $0.00 | |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-12-02 | Buy | 33,530 | $12.82 | 429,855 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-12-02 | Buy | 796 | $12.82 | 10,205 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-12-01 | Buy | 1,399 | $12.62 | 17,655 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-12-01 | Buy | 58,905 | $12.62 | 743,381 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-30 | Buy | 855 | $11.62 | 9,935 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-30 | Buy | 35,992 | $11.62 | 418,227 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-29 | Buy | 55,391 | $11.70 | 648,075 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-29 | Buy | 1,315 | $11.70 | 15,385 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-26 | Buy | 11,543 | $11.34 | 130,898 |
|
Centessa Pharmaceuticals PLC CNTA
Ordinary Shares
|
2021-11-26 | Buy | 274 | $11.34 | 3,107 |
|
Aura Biosciences Inc AURA
Series D-2 Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 373,606 | $0.00 | |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 693,525 | $14.00 | 9,709,350 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Conversion | 2,275,827 | ||
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 16,475 | $14.00 | 230,650 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Conversion | 54,065 | ||
|
Aura Biosciences Inc AURA
Series D-2 Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 8,876 | $0.00 | |
|
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 5,975 | $0.00 | |
|
Aura Biosciences Inc AURA
Series D-1 Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 39,214 | $0.00 | |
| showing 20 of 28 most recent transactions | |||||